secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001493152-26-000821
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic lowers CEO milestone threshold from $100M to $45M market cap for stock vesting
--------------------------------------------------------------------------------

- Amendment reduces first market cap milestone for CEO Vuong Trieu's restricted stock from $100M to $45M.
- Similar amendment with Jefferson Capital Ventures LLC lowers its milestone threshold to $45M.
- Company states changes are to support progress including equity line with Mast Hills and uplisting efforts.
- Other terms and milestones of the restricted stock agreements remain unchanged.
- CEO's preferred stock award is tied to the same reduced milestone; no dilution details provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315226000821/0001493152-26-000821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315226000821/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-000821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer